The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Advancements in prognostication tools in MPNs in recent years
In this video, Lindsay Rein, MD, Duke University Medical Center, Durham, NC, briefly comments on the recent advancements in the development of prognostic tools for clinicians to use when treating patients with myeloproliferative neoplasms (MPN) to allow for optimal selection and timing of therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie Pharmaceuticals, Sobi, Incyte Corporation, Morphosys, Novartis, Sumitomo Dainippon Pharma Oncology; Institutional Principal Investigator: Incyte Corporation, Novartis, Sumitomo, PharmaEssentia, Geron, Protagonist, Karyopharm, Silence Therapeutics, Blueprints Medicine, Cogent, Merck.
